KA/EN
Register
Medicines reference
Search
Search
Product

Prequillan

Favourites

Acepromazine · Fatro S.p.A.

1 form: solution. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
Solution · Cat Cat Sedation · Intramuscular / Intravenous: 1–2 mg/kgPremedication · Intramuscular / Intravenous: 0.5–1 mg/kg - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: პრექუილანი 10 მგ/მლ საინექციო ხსნარი
№ 60-11
Verified on: 22 Oct 2026
Solution · Dog Dog Sedation · Intramuscular / Intravenous: 0.5–1 mg/kgPremedication · Intramuscular / Intravenous: 0.25–0.5 mg/kg - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: პრექუილანი 10 მგ/მლ საინექციო ხსნარი
№ 60-11
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Prequillan, Solution

Acepromazine 10 mg/ml solution for injection for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Complete dog label: handling/minor-procedure sedation, base sedation with local anaesthesia and premedication for general anaesthesia
6.1/10
Situational / acceptable
vetman assessment

Prequillan

Acepromazine 10 mg/ml solution for injection for dogs and cats
Assessed clinical scopeDog · Complete dog label: handling/minor-procedure sedation, base sedation with local anaesthesia and premedication for general anaesthesia · IM,IV
Care settingMonitored veterinary-clinic IM or slow-IV use with pre-anaesthetic assessment, independent analgesia when painful and a recovery plan
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · № 60-11 · Verified on 22 Oct 2026

A pharmacologically active, authorised clinic sedative/premedicant, but the exact label doses are markedly higher than current low-dose evidence and the GB comparator. Use is situational because hypotension, breed/patient sensitivity, absent reversal and lack of analgesia demand conservative dosing and monitoring.

Regulatory and scientific credibility7.5/10

The exact product has current Georgian and Italian/EU prescription authorisations, a full-application legal basis and a detailed current SPC. Its 1983 origin, absent public exact-product outcome dossier and major dose divergence from current guidance and the GB comparator limit confidence.

Clinical efficacy6.0/10

Acepromazine reliably sedates many healthy dogs and reduces anaesthetic requirements, including in a randomized trial at 0.05 mg/kg. Response is variable, it does not provide adequate analgesia, and the exact 0.25-1 mg/kg label range is far above modern low-dose protocols, so depth and benefit are less predictable.

Safety and tolerability4.5/10

Dose-dependent hypotension, hypothermia, collapse, dysrhythmia, prolonged depression and paradoxical excitation/seizures are important and there is no specific antagonist. Label doses magnify concern; hypovolaemia, cardiac/hepatic disease, epilepsy, brachycephaly, large breeds and ABCB1 risk materially narrow safe use.

Clinical practicality6.5/10

A single clinic injection, slow-IV option and 15-30-minute premedication timing are workable. However, 10 mg/ml is poorly suited to precise contemporary low dosing, full monitoring and recovery observation are necessary, and anaesthetic/analgesic doses must be coordinated rather than administered independently.

Full-course cost-effectiveness-

Current Georgian per-procedure price was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Scope boundary: this score covers the complete authorised dog use for handling/minor-procedure sedation, local-anaesthesia support and general-anaesthesia premedication. It does not make acepromazine analgesic or appropriate for unsupervised home restraint.
  • Dose conflict: the exact dog label gives 0.5-1 mg/kg for sedation and 0.25-0.5 mg/kg for premedication. Current AAHA/trial practice and the GB AceSedate 0.03-0.125 mg/kg label are much lower; do not resolve that conflict by automatic conversion—make a documented patient-specific protocol.
  • Assess first and monitor: accurate weight, hydration/perfusion, blood pressure, rhythm, temperature, oxygenation and recovery are required. Correct hypovolaemia before use; reduce or avoid in shock, cardiac disease, debilitation, stress and old age.
  • Breed/genetic risk: large and giant dogs can be unusually sensitive; brachycephalic dogs may collapse with vagal effects, and AAHA recommends reduced doses for ABCB1-affected breeds. Start conservatively and ensure airway/circulatory rescue capability.
  • Contraindications: do not use in epilepsy, hepatic dysfunction or hypersensitivity, or with organophosphates. Convulsion, paradoxical excitation, disorientation and aggression can occur; do not leave a first-time treated patient unattended with children or other animals.
  • No analgesic substitution: acepromazine has only mild analgesic activity. Ear foreign-body removal, luxation reduction and other painful procedures need a separate evidence-based analgesic/local or general anaesthetic plan.
  • Interactions: acepromazine potentiates opioids, induction agents, inhalants, local anaesthetics and other CNS depressants. Reduce and titrate later anaesthetic doses; do not mix in the same syringe without product-specific compatibility evidence.
  • Hypotension has no specific antagonist. Provide supportive monitored management and do not use adrenaline/epinephrine for acepromazine-induced hypotension because it may worsen systemic pressure.
  • Precision/route: 10 mg/ml produces very small volumes at contemporary low doses; use a validated precision or dilution protocol. Administer IV slowly. Record actual mg/kg, volume, route, time and response rather than only “acepromazine given”.
  • Vial/handler controls: maximum 20 punctures; use within 28 days, below 25 °C and protected from light. Prevent self-injection; after accidental injection obtain urgent medical care and do not drive.
Assessment sources
  1. Prequillan GE register2026
  2. EU SPC 20242024
  3. AAHA anesthesia 20202020
  4. AAFP feline anesthesia2018
  5. AceSedate VMD control2025
  6. FDA acepromazine control2004
  7. Dog acepromazine RCT2010
  8. Cat acepromazine RCT2021
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Complete cat label: handling/minor-procedure sedation, base sedation with local anaesthesia and premedication for general anaesthesia
5.5/10
Weak evidence support
vetman assessment

Prequillan

Acepromazine 10 mg/ml solution for injection for dogs and cats
Assessed clinical scopeCat · Complete cat label: handling/minor-procedure sedation, base sedation with local anaesthesia and premedication for general anaesthesia · IM,IV
Care settingMonitored veterinary-clinic IM or slow-IV use with pre-anaesthetic assessment, independent analgesia when painful and a recovery plan
vetman score 5.5/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, veterinary · № 60-11 · Verified on 22 Oct 2026

The exact product is authorised, but feline efficacy is inconsistent and its 0.5-2 mg/kg label range is profoundly discordant with current 0.01-0.05 mg/kg guidance and hypotension data. The combination of uncertain depth, very high labelled exposure and no specific reversal makes the overall profile weak.

Regulatory and scientific credibility7.5/10

The exact product has current Georgian and Italian/EU prescription authorisations, a full-application legal basis and a detailed current SPC. Its 1983 origin, absent public exact-product outcome dossier and major dose divergence from current feline guidance and the GB comparator limit confidence.

Clinical efficacy5.0/10

Feline response is specifically described as inconsistent in current guidance. A randomized trial using 0.05 mg/kg with an opioid produced only mild sedation, while the exact label recommends 0.5-2 mg/kg; that 10-40-fold gap and absent Prequillan outcome trials make the labelled depth hard to predict.

Safety and tolerability4.0/10

The label range is 10-200 times the AAFP 0.01-0.05 mg/kg range depending on indication and endpoint. Hypotension occurred even at 0.05 mg/kg in an opioid-combination cat trial and worsened after propofol; no specific antagonist, hypothermia, prolonged depression and paradoxical reactions further narrow the margin.

Clinical practicality5.5/10

A single clinic injection is simple in principle, but a fractious cat, slow-IV access and monitoring can be difficult. The 10 mg/ml concentration makes guideline-sized feline volumes impractically small without a validated dilution/precision plan, while prolonged observation and coordinated anaesthetic reduction remain necessary.

Full-course cost-effectiveness-

Current Georgian per-procedure price was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Scope boundary: this score covers the complete authorised cat use for handling/minor-procedure sedation, local-anaesthesia support and general-anaesthesia premedication. It does not make acepromazine analgesic or a predictable stand-alone anxiolytic.
  • Major dose conflict: the exact cat label gives 1-2 mg/kg for sedation and 0.5-1 mg/kg for premedication; AAFP gives a usual 0.01-0.05 mg/kg range. This 10-200-fold divergence requires a documented patient-specific decision, not blind adherence or silent extrapolation.
  • Efficacy is variable: at 0.05 mg/kg with nalbuphine/butorphanol, a blinded trial found only mild sedation. Confirm depth before restraint or induction and have an alternative low-stress/anesthetic plan rather than repeatedly escalating an unresponsive cat.
  • Hypotension occurred in the 0.05 mg/kg combination trial and worsened after propofol. Assess hydration/perfusion and monitor blood pressure, rhythm, temperature, oxygenation and recovery; avoid in hypotension, hypovolaemia or dehydration.
  • Contraindications: do not use in epilepsy, hepatic dysfunction or hypersensitivity, or with organophosphates. Convulsion, paradoxical excitation, disorientation and aggression can occur; protect staff and patient during onset and recovery.
  • No analgesic substitution: acepromazine has only mild analgesic activity. Painful examination, foreign-body removal, reduction or surgery requires an independent analgesic/local or general anaesthetic plan.
  • Interactions: acepromazine potentiates opioids, propofol/other induction agents, inhalants, local anaesthetics and CNS depressants. Reduce and titrate later drugs; do not mix injectables without product-specific compatibility evidence.
  • No specific antagonist exists. Provide supportive monitored management for hypotension/collapse and do not use adrenaline/epinephrine for acepromazine-induced hypotension.
  • Precision/route: 10 mg/ml yields extremely small volumes at modern feline doses; use a validated precision or dilution protocol. Slow IV access may itself be unsafe in a fractious cat—choose the route within a low-stress handling plan.
  • Pregnancy/lactation safety is not established. Maximum 20 vial punctures; use within 28 days below 25 °C and protected from light. Prevent self-injection; obtain urgent medical care and do not drive after accidental injection.
Assessment sources
  1. Prequillan GE register2026
  2. EU SPC 20242024
  3. AAHA anesthesia 20202020
  4. AAFP feline anesthesia2018
  5. AceSedate VMD control2025
  6. FDA acepromazine control2004
  7. Dog acepromazine RCT2010
  8. Cat acepromazine RCT2021
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Acepromazine10 mg/ml
Formulation Type
Solution
Administration route
Intramuscular, Intravenous
Manufacturer
Fatro S.p.A. · Italy
Manufacturer (register)
Fatro S.P.A., Italy
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1333, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: პრექუილანი 10 მგ/მლ საინექციო ხსნარი
№ 60-11
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ Italian national authorisation
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified Clinic-only IM or slow IV administration after examination and accurate weighing. Label sedation: dog 0.5-1 mg/kg, cat 1-2 mg/kg. Label general-anaesthesia premedication: dog 0.25-0.5 mg/kg, cat 0.5-1 mg/kg, 15-30 minutes before induction. Start at the low end and reassess. These label doses are substantially above current guideline, trial and GB-comparator practice; do not silently extrapolate between them. Acepromazine is not adequate analgesia for a painful procedure.
Cat
WeightSedation · Intramuscular / IntravenousPremedication · Intramuscular / Intravenous
Any weight 1–2 mg/kg 0.5–1 mg/kg
  • Sedation · Intramuscular / Intravenous (single administration): Give intramuscularly or by slow intravenous injection. Start at the lower dose and increase only after assessing effect; requirements generally decrease with size and age. Do not use in epilepsy, hepatic dysfunction, hypersensitivity or with organophosphates. Reduce dose and use particular caution in debilitation, hypovolaemia, shock, cardiac disease, old age and sensitive breeds. Pregnancy/lactation safety is not established. Do not use adrenaline to reverse hypotension; acepromazine potentiates anaesthetics and other central depressants.
  • Premedication · Intramuscular / Intravenous (once, 15-30 minutes before general anaesthesia): Give intramuscularly or by slow intravenous injection. Start at the lower dose and increase only after assessing effect; requirements generally decrease with size and age. Do not use in epilepsy, hepatic dysfunction, hypersensitivity or with organophosphates. Reduce dose and use particular caution in debilitation, hypovolaemia, shock, cardiac disease, old age and sensitive breeds. Pregnancy/lactation safety is not established. Do not use adrenaline to reverse hypotension; acepromazine potentiates anaesthetics and other central depressants.
Source:
EU SPC 2024
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Prequillan 10 mg/ml solution for injection - Official Product Information
EU Veterinary Medicines Information, 2024
Dog
WeightSedation · Intramuscular / IntravenousPremedication · Intramuscular / Intravenous
Any weight 0.5–1 mg/kg 0.25–0.5 mg/kg
  • Sedation · Intramuscular / Intravenous (single administration): Give intramuscularly or by slow intravenous injection. Start at the lower dose and increase only after assessing effect; requirements generally decrease with size and age. Do not use in epilepsy, hepatic dysfunction, hypersensitivity or with organophosphates. Reduce dose and use particular caution in debilitation, hypovolaemia, shock, cardiac disease, old age and sensitive breeds. Pregnancy/lactation safety is not established. Do not use adrenaline to reverse hypotension; acepromazine potentiates anaesthetics and other central depressants.
  • Premedication · Intramuscular / Intravenous (once, 15-30 minutes before general anaesthesia): Give intramuscularly or by slow intravenous injection. Start at the lower dose and increase only after assessing effect; requirements generally decrease with size and age. Do not use in epilepsy, hepatic dysfunction, hypersensitivity or with organophosphates. Reduce dose and use particular caution in debilitation, hypovolaemia, shock, cardiac disease, old age and sensitive breeds. Pregnancy/lactation safety is not established. Do not use adrenaline to reverse hypotension; acepromazine potentiates anaesthetics and other central depressants.
Source:
EU SPC 2024
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Prequillan 10 mg/ml solution for injection - Official Product Information
EU Veterinary Medicines Information, 2024

Known Contraindications

  • Critical
    Do not use with hypovolaemia or dehydration.
    Sources: EU SPC
  • Critical
    Do not use with blood disorders or coagulopathy.
    Sources: EU SPC
  • Critical
    Do not use in anaemic animals.
    Sources: EU SPC
  • Critical
    Do not use with heart failure.
    Sources: EU SPC
  • Critical
    Do not use with lung failure.
    Sources: EU SPC
  • Critical
    Do not use in epileptic animals.
    Sources: EU SPC
  • Critical
    Do not use in neonates or dogs under 3 months.
    Sources: EU SPC
  • Critical
    Do not use if hypersensitive to acepromazine or excipients.
    Sources: EU SPC
  • Critical
    Do not use with hypotension or shock, in hypothermic animals or in a state of severe excitement. Organophosphates and procaine increase its toxicity.
    Sources: EU SPC
  • Warning
    MDR1 (ABCB1-1 delta) dogs: deeper, longer sedation; reduce the dose by 25-50%.
    Sources: EU SPC
  • Caution
    Liver disease or debility: use with caution at a reduced dose.
    Sources: EU SPC
  • Caution
    Safety in pregnancy not studied: benefit-risk only.
    Sources: EU SPC
  • Caution
    Safety in lactation not studied: benefit-risk only.
    Sources: EU SPC

Known Drug Interactions

  • Major warning Acepromazine + Metoclopramide
    Concomitant use with phenothiazine neuroleptics such as acepromazine or with butyrophenones increases the risk of extrapyramidal effects: agitation, ataxia, tremor, abnormal movements, vocalization, and aggression. Both agents block D2 receptors, producing an additive effect.
    Recommendation: Avoid the combination where possible. If necessary, use the lowest metoclopramide dose and monitor the animal. Effects are transient and resolve after treatment stops; there is no specific antidote, and a quiet environment is recommended.
  • Minor warning Buprenorphine + Acepromazine
    Centrally acting drugs, including tranquillisers, sedatives, and hypnotics, can increase buprenorphine-induced drowsiness. Combined use with sedatives can also increase depression of heart rate and respiration.
    Recommendation: Reduce the sedative dose during premedication; monitor heart rate and respiration.
  • Minor warning Dexmedetomidine + Acepromazine
    Other central nervous system depressants can potentiate dexmedetomidine; adjust the dose appropriately when they are used together.
    Recommendation: to effect
    Sources: Dexdomitor SPC
  • Minor warning Methadone + Acepromazine
    Methadone can potentiate analgesics, central nervous system depressants, and drugs that cause respiratory depression. Lower doses may be needed when these medicines are combined.
    Recommendation: Reduce doses when used in combination; monitor heart rate and respiration.
    Sources: Comfortan SPC

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (4 more) Hide additional products

Same therapeutic group 4

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗